Contract med-tech manufacturer Minnetronix to launch own device
Minnetronix is developing a product that removes contaminants in the cerebral spinal fluid after a hemorrhagic stroke.
Feasibility of Neurapheresis™ Therapy for Multidrug Resistant Gram-negative Bacterial Meningitis
October 4, 2017 - Duke University Medical Center/Minnetronix Neuro Pseudomonas, Acinetobacter and Klebsiella are three multidrug resistant (MDR) gram-negative pathogens that pose a threat to human health. Patients in hospitals…
In Vitro Characterization of the Neurapheresis™ System for the Treatment of Cryptococcal Meningitis
October 4, 2017 - Duke University Medical Center/Minnetronix Neuro Cryptococcal Meningitis is caused by Cryptococcus neoformans and is the most common cause of fungal meningitis in adults. Treatment for Cryptococcal…